Subsidiary’s self-developed Class 1 innovative drug, bemosubalimab injection, in combination therapy, has been approved for marketing.
August 13, 2026
Source: drugdu
27
On August 7, China Biopharmaceutical (01177) issued an announcement stating that its subsidiary, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., has independently developed a Class 1 innovative drug.Bemosubalimab injection in combination with chemotherapy followed by anlotinib hydrochloride capsules has been approved for marketing by the National Medical Products Administration of China for first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer.
The announcement mentioned that this is the 12th approved indication for anlotinib and the 6th approved indication for bemosubib.
https://finance.eastmoney.com/a/202608073835411830.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- A well-known generic drug company recalls 10 types of eye drops. August 13, 2026
- Big news! Zhejiang pharmaceutical company targets 500 million yuan lipid-lowering blockbuster drug August 13, 2026
- Subsidiary’s Tranexamic Acid Sodium Chloride Injection Receives Drug Registration Certificate August 13, 2026
- Lenvatinib Mesylate Capsules Receive Drug Registration Certificate August 13, 2026
- Hanyu Pharmaceutical has licensed 3SBio’s Smegglutide injection to commercialize the product, with sales milestones reaching up to 145 million yuan. August 13, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
